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The incidence of cardiovascular disease rises dramatically with age in both men and women. Because a woman’s
risk of cardiovascular disease rises markedly after the onset of menopause, there has been growing interest in the
effect of estrogen on the heart and its role in the pathophysiology of these diseases. Much less attention has been
paid to the impact of testosterone on the heart, even though the levels of testosterone also decline with age and
low-testosterone levels are linked to the development of cardiovascular diseases. The knowledge that receptors for
all major sex steroid hormones, including testosterone, are present on individual cardiomyocytes suggests that these
hormones may influence the heart at the cellular level. Indeed, it is well established that there are male-female
differences in intracellular Ca2+ release and contraction in isolated ventricular myocytes. Growing evidence suggests that
these differences arise from effects of sex steroid hormones on processes involved in intracellular Ca2+ homeostasis. This
review considers how myocardial contractile function is modified by testosterone, with a focus on the impact
of testosterone on processes that regulate Ca2+ handling at the level of the ventricular myocyte. The idea that
testosterone regulates Ca2+ handling in the heart is important, as Ca2+ dysregulation plays a key role in the
pathogenesis of a variety of different cardiovascular diseases. A better understanding of sex hormone regulation of
myocardial Ca2+ homeostasis may reveal new targets for the treatment of cardiovascular diseases in all older adults.
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Introduction
Cardiovascular diseases are a leading cause of hospitaliza-
tion and death for both men and women [1]. As advanced
age is a major risk factor for the development of cardiovas-
cular disease in both sexes, the incidence and prevalence of
these diseases is expected to escalate as our population ages
[2]. The knowledge that the incidence of cardiovascular dis-
ease in women rises as estrogen levels fall after menopause
has fueled interest in its potential cardioprotective effects
[3]. What is less well appreciated is that testosterone levels
also decline with advancing age, not just in men but in
women too [4-6]. This suggests that low-testosterone
levels may contribute to the pathogenesis of cardiovascular* Correspondence: Susan.Howlett@dal.ca
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unless otherwise stated.disease. Indeed, a number of clinical studies have shown
that low endogenous levels of testosterone are associated
with cardiovascular disease [4]. Furthermore, testosterone-
replacement therapy, which is used to treat testosterone
deficiency secondary to aging [7], may have beneficial
effects in the setting of heart failure and ischemic heart
disease [4,8,9].
Despite the popularity of testosterone supplementation
in older adults, how testosterone affects the heart is not
fully understood. The discovery of androgen receptors in
individual heart cells (myocytes) [10,11] suggests that
testosterone might modulate heart function, at least in
part, by effects on the ventricular myocytes themselves.
Here, we review emerging evidence that suggests testos-
terone influences myocardial function at the cellular level
by modifying processes involved in intracellular Ca2+
homeostasis. As disruption of Ca2+ handling plays a key
role in many cardiovascular diseases [12,13], understand-
ing the mechanisms underlying the effects of testosteronentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fluence on cardiovascular health.
Testosterone
The principal male sex hormone, testosterone, is an an-
drogen steroid. Testosterone plays important roles in nor-
mal growth and development, and its levels decline with
age in both men and women. The following discussion
provides a broad overview of testosterone, and its recep-
tors, including pathways involved in its biosynthesis, regu-
lation, and metabolism.
Testosterone in men and women
Testosterone is produced primarily by the testes in men,
although it also can be produced by the adrenal glands
and other sites including adipose tissue and bone [14,15].
It is responsible for testes descent and reproductive tract
development in the fetus, development of male secondary
sex characteristics in puberty, and the production of
sperm [16,17]. Testosterone production in men begins in
utero, rises sharply in puberty, and then declines with age
[17,18]. Indeed, the Massachusetts Male Aging Study
showed that total serum testosterone levels decline by
1.6% per year starting at age 40 [19]. Testosterone is also
produced by the ovaries, the adrenal glands, and tissues
such as adipose tissue and skin in women [6,15,20,21], al-
though serum concentrations are almost 20-fold lower in
pre-menopausal women compared to age-matched men
[22]. Interestingly, testosterone levels also decline with age
in women [6,23]. This age-dependent reduction in testos-
terone is not restricted to humans, as it is also seen in
older male rats and mice (>20 months of age) in con-
junction with a decline in fertility [24,25], although whether
levels decline in aged female animals has not been
investigated.
Biosynthesis of testosterone
Testosterone biosynthesis in men is controlled by the
hypothalamic-pituitary-gonadal axis [26], as shown in
the overview of major gonadal pathways for testosterone
biosynthesis in Figure 1. The first step is the release of
gonadotropin-releasing hormone (GnRH), which is syn-
thesized and secreted from hypothalamic neurons [27].
GnRH binds to receptors on the anterior pituitary gland
and stimulates the synthesis and secretion of luteinizing
hormone (LH) into circulation [26,28]. LH binds to LH
receptors on Leydig cells in the testes and stimulates a
G-protein, Gs, to activate the cAMP/protein kinase A
(PKA) pathway. This promotes the transport of choles-
terol into the mitochondria and increases transcriptional
activation of gene-encoding enzymes involved in testoster-
one biosynthesis [29]. The levels of testosterone in circula-
tion are under tight hormonal regulation via a negativefeedback mechanism that prevents the release of GnRH
and LH when testosterone levels are high [26].
When serum testosterone levels are low, cholesterol in
Leydig cells is transported to the inner mitochondrial
membrane via a multi-protein complex in conjunction
with the steroidogenic acute regulatory (StAR) protein
[30], as shown in Figure 1. The rate-limiting reaction in
the production of steroid hormones is the conversion of
cholesterol to pregnenolone by the cholesterol side chain
cleavage enzyme, a cytochrome P450 (CYP) enzyme
known as CYP11A1 [30]. When pregnenolone is formed,
it diffuses into the endoplasmic reticulum where testos-
terone biosynthesis proceeds via Δ4 and Δ5 pathways
(Figure 1). In the Δ4 pathway, pregnenolone is converted
to progesterone by 3β-hydroxysteroid dehydrogenase
(HSD3β) [15,31,32]. CYP17A1 converts progesterone
to 17α-hydroxyprogesterone by a hydroxylation reaction
and then to androstenedione by a lysis reaction. Testoster-
one is formed by 17β-hydroxysteroid dehydrogenase 3
(HSD17β3). In the Δ5 pathway, CYP17A1 converts
pregnenolone (via a hydroxylation reaction) to 17α-
hydroxypregnenolone followed by a lysis reaction to
yield dehydroepiandrosterone (DHEA) [15,31,32]. DHEA
is then converted to androstenedione by HSD3β. In the
final step, HSD17β3 converts androstenedione to testos-
terone. DHEA can also be converted to androstenediol by
HSD17β3 and then converted to testosterone by HSD3β
[15,31]. Some testosterone is converted to the more
potent androgen, dihydrotestosterone (DHT), by 5α-
reductase [31]. In the Leydig cells, the major andro-
gens (testosterone and DHT) leave by passive transport
into circulation, where most bind to proteins including
sex-hormone-binding globulin and/or albumin, although
some circulate as free androgen [26].
Figure 1 also demonstrates that the enzyme aromatase
can convert testosterone to the primary estrogen, 17ß-
estradiol. This is a minor pathway in the Leydig cell.
Interestingly, aromatase also is present in a number of
extragonadal sites including adipose tissue, bone, and the
brain in both men and women [33]. Furthermore, cardiac-
specific expression of aromatase has recently been shown
in the adult mouse heart [34]. Conversion of circulating
testosterone to 17ß-estradiol by these tissue-based aroma-
tase pathways may increase 17ß-estradiol levels under
conditions such as obesity [35]. Furthermore, certain ana-
bolic steroids, including testosterone esters as well as nor-
testosterone derivatives (e.g., nandrolone decanoate and
nandrolene phenpropionate), can be aromatized to estra-
diol [36]. Indeed, some anabolic steroid users take anti-
estrogens to minimize adverse effects (e.g., gynecomastia)
associated with the aromatization of testosterone deriva-
tives to estradiol [37]. Thus, effects of testosterone supple-
mentation with derivatives that can be aromatized may





























































Figure 1 Major gonadal pathways for testosterone biosynthesis. Gonadotropin-releasing hormone (GnRH) secreted from the hypothalamus releases
luteinizing hormone (LH) from the pituitary. LH binds to LH receptors on Leydig cells, stimulates Gs, and activates the cAMP/protein kinase A (PKA)
pathway. PKA promotes the transport of cholesterol into mitochondria and increases transcription of genes involved in testosterone biosynthesis.
Cholesterol is converted to pregnenolone, which diffuses into the endoplasmic reticulum for testosterone biosynthesis via Δ4 and Δ5 pathways.
Testosterone is formed by 17β-hydroxysteroid dehydrogenase 3 (HSD17β3) in the Δ4 pathway and by 3β-hydroxysteroid dehydrogenase (HSD3β) in
the Δ5 pathway. Testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase, and some are aromatized to 17ß-estradiol.
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of androgens on the cardiovascular system use the non-
aromatizable androgen DHT, rather than testosterone
or its derivatives, for example [38-40].As discussed in the ‘Testosterone in men and women’
section, there is evidence that circulating testosterone
decreases with age in both men and women [6,18,19,23].
In aging men, the fall in serum testosterone is largely
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testosterone in response to LH [41]. This arises as a result
of age-associated attenuation of the cAMP/PKA pathway,
leading to less transfer of cholesterol into the mitochon-
dria and a reduction in the production of steroidogenic
enzymes [41]. Interestingly, a similar mechanism has been
proposed to lead to the age-dependent decrease in tes-
tosterone levels in male rats [42]. In women, the age-
dependent decline in circulating testosterone is thought
to result from a combination of events including ovar-
ian failure plus a reduction in the adrenal production of
androgens [6]. Thus, the aging process reduces the amount
of testosterone available to interact with androgen recep-
tors, as described in the next section.
Androgen receptors in the heart
Biological effects of androgens are mediated by interac-
tions with androgen receptors. The effects of androgens
on androgen receptors associated with the male repro-
ductive system are well documented [43]. The knowledge
that these receptors are present in tissues such as the liver,
kidney, brain, skeletal muscle, and heart [10,44,45] has
fueled interest in the role of androgens in regulation of
physiological processes including myocardial function.
Classic receptor-binding studies provided the first evi-
dence for androgen receptors in the atria and ventricles
of the heart [46,47]. Other studies showed that mRNA
for the androgen receptor is present in cardiomyocytes
isolated from men and women, as well as in cardiomyo-
cytes from rats and dogs [10]. More recent work has
shown that androgen receptor protein is expressed in
both the atria and ventricles of male and female mice
[11]. This latter study also shows that androgen receptors
are predominantly expressed in the cytosol and nucleus of
heart tissue from adult mice [11]. Together, these studies
demonstrate that androgen receptors are present in the
heart and raise questions about the role of testosterone in
the regulation of myocardial function.
Most of the biological actions of endogenous and ex-
ogenous androgens are genomic effects mediated by an-
drogen receptors that are members of the nuclear receptor
gene superfamily. In the absence of androgens, the andro-
gen receptor forms a complex with heat-shock proteins in
the cytosol [43]. The binding of androgens causes receptor
dissociation from heat-shock proteins and translocation to
the nucleus, where the ligand-activated receptor homodi-
merizes and associates with chromatin by DNA-binding
or through binding to other chromosomal proteins [43].
This causes transcriptional activation or repression of
androgen-responsive genes, which are cell-specific ac-
cording to transcription factors and cis-acting DNA el-
ements in the particular tissue [48,49]. Transcriptional
activation of androgen-responsive genes results in slow,
long-lasting effects that can persist for hours afterandrogen receptor stimulation [50]. This androgen-
mediated transcriptional regulation is considered the
canonical/genomic pathway for testosterone signaling
and is thought to be responsible for most of the effects
of androgens on the heart, as discussed in the ‘Effects
of testosterone on cardiac contractile function’ section
below.
While the classic genomic pathway mediates many of
the biological effects of androgens, it is unlikely to be re-
sponsible for the rapid responses to androgens observed
in some tissues, including the cardiovascular system. These
transcription-independent effects are thought to be medi-
ated by the activation of a nongenomic pathway, although
the underlying molecular mechanisms are not well under-
stood [43]. For example, there is strong evidence that
testosterone induces rapid vasorelaxation in both large
arteries and smaller resistance vessels [51]. Acute appli-
cation of androgens also increases intracellular Ca2+ levels
in osteoblasts, platelets, skeletal muscle cells, neurons, and,
importantly, in cardiac myocytes [52]. Indeed, testosterone
rapidly elicits voltage-dependent Ca2+ oscillations and
IP3-receptor-mediated Ca
2+ release from internal stores in
neonatal rat cardiomyocytes [53]. While a cell-membrane-
associated androgen receptor may be responsible, at
present, its identity is unknown and other mechanisms,
such as direct activation of ion channels and signaling
pathways, may be involved [43,51,52]. Thus, although
the canonical/genomic pathway is primarily responsible
for the effects of androgens on the heart, the nonge-
nomic pathway also may contribute.
Effects of testosterone on cardiac contractile function
Influence of androgens on myocardial contractility in
humans
Clinical studies have shown that there are male-female
differences in the ability of the heart to contract, even in
the absence of cardiovascular disease. For example, women
have a higher ejection fraction at rest than men [54], but
men respond to exercise with a greater increase in ejection
fraction than women [55,56]. There is growing experimen-
tal evidence that estrogen plays a role in these male-female
differences in myocardial contractility [57], although tes-
tosterone also may contribute.
The influence of androgens on myocardial contractility
in humans has been investigated by examining the ef-
fects of anabolic-androgenic steroids on heart function.
These steroids are synthetic derivatives of testosterone
that are used therapeutically, in particular, to stimulate
muscle growth [58]. They also are used as performance-
enhancing drugs in sports, where their use is banned
due to potential unfair advantage as well as adverse effects
of high doses of these drugs [59]. While some echocardi-
ography studies report that left ventricular mass is in-
creased by anabolic steroid use [60-63], others report no
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abolished when it is indexed to fat-free body mass [68].
Echocardiography studies also have shown that ana-
bolic steroid use adversely affects myocardial function,
although again the data are not consistent. While some
report that ejection fraction is attenuated by chronic
anabolic steroid use [60,68], others have found no change
in ejection fraction in steroid users [61,63-66]. Similarly,
although some studies report that anabolic steroid use
slows cardiac relaxation [60-63,68], others report no effect
[64-66]. These divergent results likely reflect the difficul-
ties inherent in studies of anabolic steroid use. These
include differences in drugs between and within studies,
variations in the doses used and the difficulty in obtaining
a precise history of drug use in participants. Nonetheless,
these clinical studies provide evidence that testosterone
may influence cardiac contractile function. This has been
explored in more detail in pre-clinical models, as outlined
below.
The impact of testosterone on cardiac contractile function
in animal models
Various animal models have been used to investigate the
influence of testosterone on myocardial function in vivo
and in intact hearts. Some investigators have examined
the influence of long-term supplementation with testos-
terone, or other androgens, on cardiac contractile func-
tion. However, most have inferred information about
chronic testosterone effects from gonadectomy (GDX)
experiments, where animals were subjected to bilateral
removal of the testes (±testosterone replacement) for
varying periods of time. As discussed in detail below,
results of these investigations demonstrate that male sex
hormones modulate cardiac contractile function in animal
models.
Relatively little is known about the influence of testos-
terone on cardiac contractile function in animal models
in vivo, although one study has investigated the effect of
GDX on myocardial structure and function with M-mode
echocardiography [69]. These authors report that 10 weeks
of hormone deprivation attenuates contractile function, as
demonstrated by a decrease in both fractional shortening
and ejection fraction compared to hormone-replete con-
trol mice [69]. GDX also causes concentric remodeling of
the heart, characterized by increased left ventricular
posterior wall and reduced left ventricular internal diam-
eter in diastole, as well as increased relative wall thickness
when compared to intact males [69]. These echocardio-
graphic data suggest that prolonged absence of male sex
hormones modifies the structure and function of the
heart. Still, whether this affects cardiac relaxation and pro-
motes diastolic dysfunction has not yet been investigated
with techniques such as tissue Doppler. Such studies
would be of considerable interest, as there is evidencethat GDX slows relaxation in intact hearts and in iso-
lated myocytes, as discussed below.
A number of studies have explored the effects of tes-
tosterone supplementation on myocardial contractility in
intact hearts isolated from various animal models. These
studies typically used various anabolic-androgenic steroids
at high doses to mimic anabolic steroid abuse in exercise
training. Most found that chronic administration (8–12
weeks) of 5–50 mg/kg/week of anabolic steroid (e.g., nan-
drolone decanoate, stanozolol, or 17α-methyltestosterone)
suppresses peak left ventricular contractile performance in
young adult rats ([70-72] but c.f. [73]). By contrast, high
doses of anabolic steroids have no effect on the rates of
left ventricular pressure rise (+dP/dT) or the rates of left
ventricular pressure decay (−dP/dT), which indicates that
these agents do not affect the time course of contraction
or relaxation ([70,71,73] but c.f. [72]). The impact of more
physiological steroid concentrations also has been exam-
ined. Eleawa et al. [74] treated young intact rats with con-
centrations of testosterone propionate (1.5 mg/kg/week;
12 weeks) designed to produce plasma testosterone
levels between 3–11 ng/ml, to mimic more physiological
concentrations. They found that these lower levels of tes-
tosterone had no effect on left ventricular developed pres-
sure (LVDP), +dP/dT, or − dP/dT in Langendorff-perfused
hearts [74]. These observations indicate that while high
levels of anabolic-androgenic steroids can negatively affect
peak cardiac contractile performance, lower concentra-
tions have few effects in animal models.
Other investigators have examined the influence of
chronic testosterone withdrawal on cardiac contractility
in GDX rodents, as summarized in Table 1. Studies in
Langendorff-perfused hearts show that LVDP is not af-
fected by short-term (2–9 weeks) GDX [75,76], but de-
clines after longer-term GDX (e.g., 16 weeks) [74]. There
is evidence that these deficits in contractile function in
low-testosterone states may be more prominent at high
physiological loads (Table 1). For example, LVDP is atten-
uated 3–10 weeks after GDX in working hearts models,
but only when hearts are exposed to high left atrial
pressures [77,78]. Furthermore, although left ventricular
end-diastolic pressure (LVEDP) is unaffected by GDX in
Langendorff-perfused [75] and catheterized hearts [69], it
declines when GDX hearts are subjected to high left atrial
pressures [77,78]. The time course of contraction is also
modified by withdrawal of male hormones (Table 1).
While most studies report that + dP/dT is not affected
by GDX ([69,76] but c.f. [74]), there is evidence that -dP/dT
is slowed following GDX ([74,77,78] but c.f. [69,76]).
Consistent with these results, recent work has shown
that + dP/dT is also slower in young adult male mice
that overexpress aromatase and have much lower tes-
tosterone levels (and higher estrogen levels) compared to
wild type controls [79]. Interestingly, these changes in the
Table 1 Influence of chronic testosterone withdrawal on myocardial contractility
Component Model Functional change Duration of GDX (weeks) Species Reference
LVDP Langendorff ↔ 2 Rat [75]
↔ 9 Rat [76]
a↓ 16 Rat [74]
Working heart b↓ 3 Rat [77]
b↓ 10 Rat [78]
LVEDP Millar catheterization ↔ 10–11 Mouse [69]
Langendorff ↔ 2 Rat [75]
Working heart b↓ 3 Rat [77]
b↓ 10 Rat [78]
+dP/dT Millar catheterization ↔ 10–11 Mouse [69]
Langendorff ↔ 9 Rat [76]
a↓ 16 Rat [74]
−dP/dT Millar catheterization ↔ 10–11 Mouse [69]
Langendorff ↔ 9 Rat [76]
a↓ 16 Rat [74]
Working heart b↓ 3 Rat [77]
b↓ 10 Rat [78]
aEffect of GDX is reversed by testosterone replacement. bFunctional change in the working heart model was only observed at high left atrial pressures.
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from GDX animals are reversed by testosterone replace-
ment [74]. Together, these observations suggest that
chronic testosterone withdrawal attenuates peak contrac-
tion and slows relaxation, especially when hearts are
working under high loads. As cardiac contraction is initi-
ated by a transient rise in cytosolic Ca2+ in individual
cardiomyocytes, effects of testosterone on contractile
function may arise from effects on mechanisms involved
in intracellular Ca2+ handling, as discussed below.
Long-term influence of testosterone on cellular Ca2+ handling
The process by which cardiac excitation triggers a rise in
intracellular Ca2+ and contraction is known as excitation-
contraction coupling (reviewed by [80,81]). This process is
initiated when Ca2+ enters the cell via L-type Ca2+ chan-
nels during phase 2 of the action potential (AP). This
small influx of Ca2+ triggers the release of a much larger
amount of Ca2+ through Ca2+ release channels (ryanodine
receptors (RyRs)) in the sarcoplasmic reticulum (SR) in a
process known as Ca2+-induced Ca2+ release [12,81]. Ca2+
is released from the SR in the form of discrete, subcellular
units called Ca2+ sparks that fuse to form the Ca2+ transi-
ent [82]. Ca2+ then binds to contractile proteins, known as
myofilaments, which results in sarcomere shortening and
cardiac contraction. Relaxation occurs when Ca2+ is taken
back up into the SR by the sarco/endoplasmic reticulum
Ca2+-ATPase (SERCA), whose activity is regulated by
the endogenous inhibitor, phospholamban (PLB). Some
Ca2+ is also removed from the cell on a beat-to-beat basis,primarily by the bidirectional Na+/Ca2+ exchanger (NCX)
that removes one Ca2+ in exchange for 3 Na+ [83]. The ef-
fects of testosterone on cardiac contractile function may
arise through effects on components of the excitation-
contraction coupling pathway at the level of the myocyte.
Testosterone and the cardiac action potential
As SR Ca2+ release and contraction are initiated by the
cardiac AP, some investigators have explored the influ-
ence of testosterone on AP properties (Table 2). Chronic
exposure to testosterone itself has no effect on resting
membrane potential (RMP), AP amplitude, or AP dur-
ation at 50% repolarization (APD50) but actually prolongs
APD95 in rat papillary muscle [84]. By contrast, more re-
cent work in isolated mouse ventricular myocytes has
shown that, while chronic DHT treatment has no effect
on RMP, it does cause a marked abbreviation of both
APD50 and APD90 [39]. One factor that might account for
discrepancies between these two studies is the difference
between chronic exposures to testosterone versus DHT.
As reviewed in the ‘Biosynthesis of testosterone’ section,
testosterone can be converted to estrogen by the enzyme
aromatase whereas DHT cannot [33,36]. Therefore, estro-
gen may contribute to observed effects in studies where
testosterone is used as the androgen receptor ligand [84].
Consistent with this idea, chronic exposure to estrogen
has been shown to prolong APD in some models [57], in
particular, when animals are in the estrus stage where es-
trogen levels peak [85-87]. Thus, apparent prolongation of
APD by testosterone may be due to estradiol produced by
Table 2 Impact of chronic androgen treatment and GDX on resting and action potentials
aComponent Treatment Duration (weeks) Preparation Functional change Species Reference
Testosterone supplementation
RMP bTestosterone 4 Ventricular muscle ↔ Rat [84]
cDihydrotestosterone 13 Ventricular myocyte ↔ Mouse [39]
AP amplitude bTestosterone 4 Ventricular muscle ↔ Rat [84]
APD50 bTestosterone 4 Ventricular muscle ↔ Rat [84]
cDihydrotestosterone 13 Ventricular myocyte ↓ Mouse [39]
APD90/95 bTestosterone 4 Ventricular muscle ↑ Rat [84]
cDihydrotestosterone 13 Ventricular myocyte ↓ Mouse [39]
Gonadectomy (GDX)
RMP GDX 4 Ventricular muscle ↔ Rat [84]
11–15 Ventricular myocyte ↔ Mouse [39]
AP amplitude GDX 4 Ventricular muscle ↔ Rat [84]
APD50 GDX 4 Ventricular muscle ↑ Rat [84]
11–15 Ventricular myocyte ↑ Mouse [39]
APD90/95 GDX 4 Ventricular muscle ↔ Rat [84]
11–15 Ventricular myocyte ↑ Mouse [39]
aAll experiments used paced tissues and myocytes from male animals only. bTestosterone treatment with 5 mg/kg/day. cDihydrotestosterone treatment with a
7.5-mg pellet.
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chronic exposure to androgens actually abbreviates APD.
Information about the effects of testosterone on the
cardiac AP also has been inferred from studies where
animals were subjected to bilateral GDX through removal
of the testes. The results of these investigations also are
summarized in Table 2. It seems clear that GDX has no ef-
fect on either RMP or AP amplitude [39,84]. By contrast,
there is general agreement that GDX prolongs APD50
[39,84] and APD90/95 ([39] but c.f. [84]) in both intact ven-
tricular muscle and in isolated ventricular myocytes
(Table 2). Taken together with the DHT work reviewed
above, these observations suggest that chronic exposure
to testosterone abbreviates the cardiac AP, and in its ab-
sence, APD is prolonged. The shape of the cardiac AP is
inextricably linked to SR Ca2+ release and contraction
[85]. Thus, the increase in APD seen following GDX may
prolong SR Ca2+ release, increase the duration of contrac-
tion, and slow relaxation. Thus, prolongation of the AP
may help explain the prolonged relaxation times seen in
the hearts of GDX animals (Table 1).
The influence of testosterone on transarcolemmal ion fluxes
GDX may act to prolong the cardiac AP by modifying
ionic currents to either attenuate repolarization or pro-
long depolarization. Therefore, a number of investigators
have examined the influence of GDX on sarcolemmal
proteins and currents, as shown in Table 3. Most studies
have examined repolarizing K+ currents in rodent models
13 to 16 weeks after GDX (Table 3). There is generalagreement that GDX has no effect on transient outward
current (ITO), steady state K
+ current (ISS) and inward
rectifier K+ current (IK1), or on the expression of pro-
teins or mRNA levels linked to these currents [38,74].
By contrast, GDX reduces the magnitude of the ultra-
rapid delayed rectifier K+ current (IKur) and decreases
the expression of the corresponding Kv1.5 protein ([38]
but c.f. [74]). This reduction in peak IKur could contrib-
ute to the prolongation of the APD in rodent models.
In the rabbit model, where the slow delayed rectifier K+
current (IKs) is the major repolarizing current [88], peak
IKs also is slightly reduced by GDX [89]. These observa-
tions suggest that long-term testosterone withdrawal at-
tenuates repolarizing currents, which may help explain
the longer APs seen in cardiac muscle and myocytes from
GDX animals.
Prolongation of the AP by GDX also could arise through
changes in ionic currents that prolong depolarization.
Whether Na+ currents are influenced by GDX has not yet
been investigated. However, a few studies have investi-
gated the effect of GDX on L-type Ca2+ current (ICa-L), as
shown in Table 3. Voltage-clamp studies show that GDX
has no effect on peak ICa-L, at least in the rabbit model
[40]. By contrast, the density of 1,4-dihydropyridine
(DHP) receptors (L-type Ca2+ channels) is markedly re-
duced by GDX in hearts from male rodents, and this ef-
fect is reversed by testosterone replacement [90,91].
This suggests that GDX may actually reduce Ca2+ in-
flux in the heart. In support of this, peak L- and T-type
Ca2+ currents are enhanced in neonatal rat cardiomyocytes
Table 3 Influence of gonadectomy on sarcolemmal proteins and currents
Component Treatment Duration (weeks) Functional change Species Reference
Ultra-rapid delayed rectifier K+ current (IKur) aGDX 13 ↓ peak IKur Mouse [38,39]
13 ↓ Kv1.5 protein Mouse [38,39]
GDX 16 ↔ Kv1.5 protein Rat [74]
Transient outward K+ current (ITO) GDX 13 ↔ peak ITO Mouse [38]
13 ↔ Kv4.2/4.3 protein Mouse [38]
Steady state K+ current (ISS) GDX 13 ↔ peak ISS Mouse [38]
13 ↔ Kv1.2 protein Mouse [38]
Inward rectifier K+ current (IK1) GDX 13 ↔ peak IK1 Mouse [38]
13 ↔ Kir2.1 protein Mouse [38]
16 ↓ Kir2.1 mRNA Rat [74]
16 ↔ Kir2.2 mRNA Rat [74]
16 ↔ Kir2.3 mRNA Rat [74]
Slow delayed rectifier K+ current (IKs) GDX 8 ↓ peak IKs Rabbit [89]
L-type Ca2+ current (ICa-L)/ dihydropyridine receptor (DHPR) GDX 9 ↔ peak ICa-L Rabbit [40]
bGDX 2 ↓ DHPR mRNA Rat [90]
16 ↓ DHPR mRNA Rat [91]
Na + -Ca2+ exchanger GDX 10 ↔ NCX activity Rat [96]
9 ↔ NCX activity Rat [76]
2 ↔ NCX protein Rat [75]
10 ↓ NCX protein Rat [96]
10–11 ↑ NCX protein Mouse [69]
bGDX 2 ↓ NCX mRNA Rat [90]
16 ↓ NCX mRNA Rat [91]
aIndicates that the effect of GDX was reversed by treatment with dihydrotestosterone. bIndicates that the effect of GDX was reversed by treatment with testosterone.
Ayaz and Howlett Biology of Sex Differences  (2015) 6:9 Page 8 of 15chronically exposed to testosterone (24–30 h in culture),
an effect blocked by the nuclear androgen receptor antag-
onist, flutamide [92,93]. Chronic exposure to DHT also in-
creases peak ICa-L and increases the expression of Cav1.2
(the pore-forming subunit of the L-channel) in cultured
human ventricular myocytes [94]. These findings suggest
that testosterone increases inward Ca2+ currents and that
this effect is attenuated by GDX. Thus, Ca2+ influx may ac-
tually be inhibited by GDX, so enhanced Ca2+ influx does
not account for the increase in APD observed in the GDX
heart. On the other hand, Ca2+ influx via ICa-L is the pri-
mary trigger for SR Ca2+ release. Thus, effects of testoster-
one on ICa-L could have important effects on cardiac
contractility as discussed in the next section.
Another important sarcolemmal protein that regulates
intracellular Ca2+ levels is NCX. This exchanger primar-
ily operates to remove one Ca2+ from the cell in ex-
change for three Na+ [95]. This generates an inward
current that helps maintain the AP plateau [95] and
could, in theory, help prolong APD in GDX. Whether
NCX is modified by testosterone has been investigated
in GDX rodents with biochemical and molecular ap-
proaches (Table 3). While several studies have shownthat NCX activity and protein expression are unchanged
2 to 10 weeks after GDX [75,76,96], others report that
NCX protein levels are reduced ([96] but c.f. [69]). There
is also evidence that mRNA levels decline after both
short-term (2 weeks) and long-term (16 weeks) GDX,
and this effect is abolished by testosterone supplementa-
tion [90,91], as shown in Table 3. As NCX helps remove
Ca2+ from the cell, a reduction in NCX in GDX hearts
could slow relaxation, as observed in perfused hearts
from GDX animals (Table 1). Still, at present, there is no
consensus on the effect of GDX on NCX, and it is un-
certain whether NCX helps prolong the APD.
Testosterone affects contractions and Ca2+ release in
individual cardiomyocytes
Previous experimental studies have shown that chronic
testosterone withdrawal attenuates cardiac contractility
in vivo (the ‘The impact of testosterone on cardiac con-
tractile function in animal models’ section). GDX also
reduces peak contraction and slows relaxation in isolated
perfused hearts, especially when hearts are working
under high loads (the ‘The impact of testosterone on
cardiac contractile function in animal models’ section;
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could arise, in part, because the ability of individual ven-
tricular myocytes to contract is modified by testosterone.
For example, there is some evidence that cardiomyocyte
contractions are larger in cells from male animals when
compared to females (reviewed by [57]). Furthermore,
chronic testosterone treatment (24 h in culture) en-
hances peak contractions, measured as unloaded cell
shortening, in isolated rat cardiomyocytes [97]. Larger
contractions are also observed in cells from female aro-
matase knockout mice, who have elevated testosterone
levels along with low-estrogen levels [98]. Studies in
myocytes from GDX rats also provide some support for
these observations (Table 4). While one investigation
showed that peak contractions are not affected by GDX
[91], another found that peak responses are attenuated
by testosterone deprivation [99]. On balance, these stud-
ies suggest that testosterone enhances peak contraction
and testosterone deprivation may suppress contraction
at the level of the cardiomyocyte.
Other studies have investigated the influence of testos-
terone on the rate of relaxation of contraction. There is
evidence that the rates of relaxation are faster in cardio-
myocytes from male animals than in cells from females
(reviewed by [57]). Likewise, chronic exposure to testos-
terone (24 h in culture) increases the rate of relaxation
in individual rat myocytes [97], while testosterone with-
drawal slows cardiomyocyte relaxation [91,99], as shown
in Table 4. Female aromatase knockout mice (with high
testosterone and low estrogen) also exhibit faster con-
tractions than wild type controls [98]. These findings
suggest that the slower − dP/dT reported in many stud-
ies of perfused GDX hearts ([74,77,78] but c.f. [69,76]) is
attributable, at least in part, to prolongation of contrac-
tion at the cellular level.
Testosterone could modify cardiac contractile function
by effects on the contractile proteins themselves. How-
ever, few studies have examined the impact of testoster-
one on myofilament proteins. One study has shown that
testosterone deprivation has no effect on myofilament Ca2+
sensitivity but reduces maximal myofilament responsesTable 4 Gonadectomy modifies cardiomyocyte Ca2+ release a
Parameter Component Functional change [Ca2+] (m
Cell shortening Peak contraction ↔ 1
a↓ 0.5–2
Relaxation rate aSlowed 1
0.5–2
Intracellular Ca2+ Peak Ca2+ transient ↔ 1
a↓ 0.5–2
Ca2+ transient decay rate aSlowed 0.5–2
1
aIndicates that the effect of GDX was reversed by treatment with testosterone in stto Ca2+ in skinned rat ventricular muscle [96]. This de-
crease in maximal responsiveness to Ca2+ could contrib-
ute to the reduction in contractility observed in GDX
hearts. Another study has examined myosin heavy chain
(MHC) composition in sham-operated and GDX rat
hearts [100]. They found that GDX causes a shift from the
fast α-MHC isoform to the slower ß-MHC isoform, and
this is reversed by testosterone replacement [100]. Pre-
dominance of the slower ß-MHC isoform could contrib-
ute to the slowing of relaxation in isolated cardiomyocytes
and perfused hearts from GDX animals.
Others have investigated whether the influence of tes-
tosterone on cardiac contraction is mediated by changes
in underlying Ca2+ transients (Table 4). There is some
evidence that Ca2+ transients are larger and, in particu-
lar, faster in myocytes from males than females
(reviewed by [57]). Female aromatase knockout mice
(high-testosterone and low-estrogen levels) also exhibit
larger and faster Ca2+ transients when compared to wild
type [98]. Furthermore, although one study showed that
Ca2+ transients are not affected by GDX [76], another
reported that peak responses are attenuated by GDX
[99]. As with myocyte contraction, there is general
agreement (Table 4) that GDX slows the rate of decay of
the Ca2+ transient in isolated cardiomyocytes [76,99].
These findings suggest that the smaller, slower contrac-
tion characteristic of GDX myocytes and hearts are at-
tributable, at least in part, to changes in the underlying
Ca2+ transients.
Interestingly, studies that report no change in peak
contractions and Ca2+ transients after GDX [76,91] use
external Ca2+ concentrations and pacing frequencies far
below physiological for rats (e.g., 1 mM Ca2+; 0.2–
0.5 Hz). By contrast, Curl et al. [99], who also used low-
pacing rates (e.g., 0.5 Hz), used a range of external Ca2+
concentrations (e.g., 0.5–2 mM) and found that peak
contractions and Ca2+ transients declined after GDX, es-
pecially at higher external Ca2+ concentrations (Table 4).
These data suggest that the influence of GDX on peak car-
diac contraction may become evident when cardiomyo-
cytes are working under more physiological conditions. Asnd contraction
M) Pacing rate (Hz) Duration of GDX (weeks) Species Reference
0.5 16 Rat [91]
0.5 2 Rat [99]
0.5 16 Rat [91]
0.5 2 Rat [99]
0.2 9 Rat [76]
0.5 2 Rat [99]
0.5 2 Rat [99]
0.2 9 Rat [76]
udies by Curl et al. [99] and Golden et al. [91].
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greatest when hearts are working at high loads [77,78], ex-
periments that expose GDX myocytes to higher pacing
frequencies could be informative.
In theory, testosterone may modulate other aspects of
Ca2+ handling in the cardiomyocyte. For example,
whether the rate of rise of the Ca2+ transient is modified
by GDX has not yet been investigated. Changes in the
Ca2+ transient rise time in GDX hearts could reflect de-
synchrony of Ca2+ release mechanisms in the SR [101].
Furthermore, whether diastolic Ca2+ levels are modified
by testosterone has not been examined. Higher diastolic
Ca2+ levels would be expected if SR Ca2+ sequestration
is slowed by GDX, as suggested by the longer Ca2+ tran-
sient decay rates seen in cells from GDX animals
[76,99]. The next section reviews studies that have inves-
tigated the influence of chronic testosterone withdrawal
on specific intracellular Ca2+-handling mechanisms in
the heart.
Testosterone targets SR Ca2+-handling mechanisms in the
cardiomyocyte
The SR plays a crucial role in Ca2+ release and reuptake
within the cardiomyocyte, so a number of investigators
have examined the influence of testosterone on SR Ca2+
release mechanisms (Table 5). As with most studies, the
influence of testosterone on processes involved in SR
Ca2+ handling has largely been inferred from studies
done on animals subjected to GDX. Although there isTable 5 Effect of gonadectomy on Ca2+ handling by the sarco
Component Functional change D
SR Ca2+ release ↔ RyR2 protein 2
a ↓ RyR-mediated 45Ca2+ flux 9
SR Ca2ccps stores ↔ Calsequestrin protein 1
↔ Calreticulin protein 1
a↓ SR Ca2+ content 9
SERCA2a ↔ SERCA2a protein 2
1
1
↔ SERCA activity 1
a↓ SERCA activity 9




a↓ PLB Thr17 phosphorylation 1
1
↓ PLB Ser16 phosphorylation 1
↔ PLB Ser16 phosphorylation 1
aIndicates that the effect of GDX was reversed by treatment with testosterone in stno indication that RyR protein levels are affected by
GDX [75], RyR-mediated 45Ca2+ flux is actually reduced
following GDX in the rat model [76]. In support of this
observation, chronic exposure to testosterone (24–30 h
of culture) increases the amplitude of subcellular SR Ca2+
release units known as Ca2+ sparks [92]. Furthermore,
Ca2+ sparks are larger in cardiomyocytes from male ani-
mals when compared to females [102,103]. Taken to-
gether, these findings suggest that testosterone enhances
SR Ca2+ release by increasing the magnitude of individual
Ca2+ sparks and that chronic testosterone withdrawal sup-
presses this process. If SR Ca2+ release events are reduced
by GDX, this could account for the reduction in peak con-
traction observed in both intact hearts and cardiomyo-
cytes from GDX animals. Additional studies that explore
the role of testosterone in regulating Ca2+ sparks via sig-
naling pathways such as those mediated by PKA and Ca2+
calmodulin-dependent kinase II (CaMKII) [102,104,105]
would be of interest.
Most investigations of the influence of testosterone on
SR function have focussed on its effects on SR Ca2+ con-
tent and SR Ca2+ reuptake mechanisms. Studies have
shown that levels of the SR Ca2+-binding proteins calse-
questrin and calreticulin are not affected by GDX [69].
However, SR Ca2+ content is reduced in myocytes from
GDX animals when compared to sham-operated con-
trols [76]. The mechanism responsible for the reduction
in SR Ca2+ content in the setting of chronic testosterone
withdrawal has been investigated. Table 5 shows that theplasmic reticulum



















udies by Tsang et al. [76] and Witayavanitkul et al. [96].
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CA2a, is not affected by GDX [69,75,96]. Thus, there is
no evidence that a reduction in the expression of SER-
CA2a can account for the decrease in SR Ca2+ content
in GDX hearts.
Other investigators have examined the expression of
the endogenous SERCA2a inhibitor, PLB, after chronic
testosterone withdrawal (Table 5). There is good agree-
ment that PLB protein expression is similar in sham-
operated and GDX hearts [69,75,76,96]. However, the
regulation of PLB by key signaling pathways is modified
by GDX. It is well known that PLB is regulated by phos-
phorylation through both PKA and CaMKII pathways
[106]. As shown in Table 5, there is strong evidence that
phosphorylation of PLB at the CaMKII site (Thr17) is re-
duced by GDX [69,96]. There is also evidence that PLB
phosphorylation at the PKA site (Ser16) is reduced by
GDX [69], although this is not seen in all studies [96].
As phosphorylation of PLB at both the PKA and CaM-
KII sites increases the activity of SERCA2a [106], a re-
duction in phosphorylation at these sites would be
expected to reduce SERCA2a activity. This agrees with
reports that SERCA activity is reduced by GDX ([96] but
c.f. [76]). This reduction in the rate of SR Ca2+ may explain
the slower Ca2+ transient decay [76,99] and reduction in
SR Ca2+ content [76] characteristic of cardiomyocytes from
GDX animals.
Although information is limited, there is evidence that
the cAMP/PKA and CaMKII pathways are modulated
by androgens. It is known that cAMP levels are higher
in cardiomyocytes from young adult male mice when
compared to females [102]. While this is due, at least in
part, to increased expression of phosphodiesterase 4B in
female cells [102], testosterone also may play a role. In
support of this, testosterone has been shown to inhibit
phosphodiesterase and increase cAMP levels in rat atria
and ventricles [107]. Thus, cAMP would be expected to
fall in animals subjected to chronic GDX. Testosterone-
associated changes in the CaMKII pathway also are
likely to occur in the setting of GDX, as CaMKII is acti-
vated by intracellular Ca2+, which is reduced by GDX
(Table 4). Additional studies that explore the impact of
androgens on pathways involved in post-translational
modifications of SR Ca2+ release mechanisms in the
heart would be of interest.
Acute effects of testosterone on cardiac Ca2+-handling
mechanisms
Although most studies have explored the effects of
chronic testosterone exposure and/or deprivation on the
heart, others have examined acute (nongenomic) effects
of testosterone in cardiac muscle and isolated cardio-
myocytes. It is well established that physiological testos-
terone levels fluctuate between 10 and 35 nM in adultmen [108], and similar levels are seen in male rodents
[109]. However, as outlined below, experimental studies
of acute testosterone application have typically used
supra-physiological concentrations to assess actions on
cardiac Ca2+-handling mechanisms.
There is evidence that testosterone can acutely affect
the cardiac AP, at least when higher concentrations of
androgens are used. Acute application of testosterone
has no effect on RMP but prolongs APD in guinea pig
papillary muscle preparations when high concentrations
are used (e.g., 1,000 μM) [110]. On the other hand, acute
application of lower concentrations of testosterone (e.g.,
100 nM) actually shortens APD in guinea pig ventricular
myocytes [111]. Furthermore, lower concentrations of
testosterone also can acutely affect ionic currents in iso-
lated cardiomyocytes. For example, Michels et al. [93]
reported that 10 μM testosterone reduces peak T-type
Ca2+ current in neonatal rat cardiomyocytes. Further-
more, even lower concentrations of testosterone (100
nM) inhibit peak ICa-L in ventricular myocytes isolated
from neonatal rats [92] and adult guinea pigs [111].
Superfusion of isolated rabbit ventricular myocytes with
3 to 10 nM concentrations of the potent androgen DHT
increases the magnitude of IK1 [112] and application of
100 nM testosterone enhances IKs in guinea pig ven-
tricular myocytes [111]. These studies demonstrate that
testosterone and its analogs can acutely modify the car-
diac AP and underlying ionic currents, although whether
these effects are relevant in vivo is unclear because most
studies used supra-physiological concentrations of drug.
Others have examined effects of acute testosterone ap-
plication on cardiomyocyte Ca2+ handling directly. One
group has shown that acute application of testosterone
(100 nM) elicits voltage-dependent oscillations in intra-
cellular Ca2+, along with IP3-receptor-mediated Ca
2+
release from SR stores in neonatal rat ventricular myo-
cytes [53]. By contrast, another study demonstrated that
acute application of 1 μM testosterone had no effect on
either the amplitudes or time courses of contractions in
ventricular myocytes isolated from adult female rats
[113]. This latter study also showed that 1 μM testoster-
one did not affect the amplitude or time course of the
Ca2+ transient [113]. Whether differences between neo-
natal and adult ventricular myocytes account for these
differing results is not yet clear. Importantly, the Beesley
et al. [113] study showed that even high concentrations
of testosterone have no acute effects on Ca2+ homeosta-
sis or contractions in cells from females. As most studies
of the effects of testosterone on the heart have used cells
from males, it is possible that there are male-female dif-
ferences in responses to testosterone, and additional
studies to address this issue are needed. These acute ef-
fects of androgens on the heart are seen only at high
concentrations of steroid, so the physiological relevance
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plore the impact of more physiological concentrations
on cardiac Ca2+-handling mechanisms are warranted.
Conclusions
The evidence reviewed here suggests that chronic testos-
terone withdrawal influences cardiac Ca2+-handling
mechanisms in ventricular myocytes, as illustrated in
Figure 2. APD is prolonged in the absence of testoster-
one, an effect mediated by a decrease in magnitude of
the repolarizing K+ current, IKur, at least in rodent
models. This reduction in IKur is secondary to a decrease
in the expression of Kv1.5. Ca2+ transients also are
smaller and slower in ventricular myocytes from GDX
animals when compared to sham-operated controls, es-
pecially when cells are paced at physiological rates. The

















Figure 2 Impact of GDX on intracellular Ca2+-handling mechanisms in ven
GDX, due to a decrease in repolarizing K+ currents (IKur) and a reduction in
sparks attenuates SR Ca2+ release. Ca2+ transient decay is slowed by longer AP
of PLB by CaMKII (and possibly PKA). Peak contractions are attenuated throug
responsiveness to Ca2+. Contractions are slowed because SR Ca2+ uptake is re
activity or expression is affected by GDX is not yet clear.changes in several components of the excitation-
contraction coupling pathway. First, GDX reduces the
density of L-type Ca2+ channels, so Ca2+ influx is re-
duced and there is less Ca2+ available to trigger SR Ca2+
release. Second, the amount of SR Ca2+ available for re-
lease is reduced by GDX, and the magnitude of Ca2+
sparks may decline. The decay of the Ca2+ transient is
slowed as a consequence of a decrease in the rate of SR
Ca2+ uptake along with prolongation of the APD. The
decline in SR Ca2+ uptake arises through a reduction in
phosphorylation of PLB by CaMKII and possibly also by
PKA. Contractions are attenuated in GDX myocytes due
to a decrease in the magnitude of the Ca2+ transient
along with a reduction in the maximal myofilament re-
sponsiveness to Ca2+. Relaxation is slowed due to slower
Ca2+ transient decay along with a shift from the fast α-















tricular myocytes isolated from rodent hearts. APD is prolonged by
the expression of Kv1.5. Reduced Ca2+ influx along with smaller Ca2+
s and slower SR Ca2+ uptake mediated by a decrease in phosphorylation
h smaller peak Ca2+ transients and a decrease in maximal myofilament
duced and the slower β-MHC isoform predominates. Whether NCX
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anisms involved in Ca2+ homeostasis and suggest that
testosterone modulates myocardial function, at least in
part, by effects on individual ventricular myocytes in ro-
dent models. Additional experiments that explore the
impact of testosterone on these mechanisms in cardio-
myocytes from larger mammals including humans are
needed and the key signaling pathways involved should
be identified.
The idea that testosterone regulates the cardiac ac-
tion potential and Ca2+ homeostasis at the level of the
individual heart cell has a number of important clinical
implications. For example, men have faster rates of re-
polarization than women [114], and castrated men have
prolonged repolarization while the reverse is seen in
women with abnormally high levels of testosterone
[115]. This is consistent with evidence that GDX in-
creases APD in individual myocytes in animal models.
This may be clinically important as prolongation of the
AP can increase the probability of early after depolar-
izations, which can trigger arrhythmias such as torsades
des pointes [116,117]. Furthermore, it is well known
that levels of testosterone decline with age, at the same
time as the incidence of cardiovascular disease rises.
Modifications in myocardial Ca2+ handling and con-
traction linked to falling testosterone levels in older
adults are likely to interact with diseases in the aging
heart. For example, the observation that contractions
and Ca2+ transients decline in low-testosterone states
may promote heart failure with reduced ejection frac-
tion [118]. Intracellular Ca2+ dysregulation also is im-
plicated in the pathogenesis of diseases such as
myocardial ischemia and arrhythmias [119], where a
decrease in testosterone may influence disease expres-
sion. Improved understanding of the cellular mecha-
nisms involved in the effects of testosterone on the
heart may reveal mechanisms involved in the increase
in susceptibility to cardiovascular diseases in aging and
may ultimately help identify new targets for interven-
tion in the treatment of these diseases in both men and
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